



# Trends in COVID-19-associated mortality in patients with pulmonary hypertension: a COMPERA analysis

Kai-Helge Schmidt<sup>1</sup>, Katrin Milger<sup>2</sup>, Christine Pausch<sup>3</sup>, Doerte Huscher<sup>4</sup>, David Pittrow<sup>3,5</sup>, Ekkehard Grünig<sup>6</sup>, Gerd Staehler<sup>7</sup>, Henning Gall<sup>8,9</sup>, Oliver Distler<sup>10</sup>, Dirk Skowasch<sup>11</sup>, Michael Halank<sup>12</sup>, Heinrike Wilkens<sup>13</sup>, Matthias Held<sup>14</sup>, Hans Klose<sup>15</sup> and Marius M. Hoeper<sup>9,16</sup>

<sup>1</sup>Department of Cardiology and Center of Thrombosis and Hemostasis (CTH), University Medical Center Mainz, Mainz, Germany. <sup>2</sup>Department of Medicine V, University Hospital, LMU Munich, Comprehensive Pneumology Center Munich (CPC-M), member of the German Center for Lung Research (DZL), Munich, Germany. <sup>3</sup>GWT-TUD GmbH, Innovation Center Real-World Evidence, Dresden, Germany. <sup>4</sup>Institute of Biometry and Clinical Epidemiology, and Berlin Institute of Health, Charité-Universitätsmedizin, Berlin, Germany. <sup>5</sup>Institute for Clinical Pharmacology, Medical Faculty, Technical University, Dresden, Germany. <sup>6</sup>Center for Pulmonary Hypertension, Thoraxklinik at Heidelberg University Hospital, Translational Lung Research Center Heidelberg (TLRC), German Center for Lung Research (DZL), Heidelberg, Germany. <sup>7</sup>Fachklinik Löwenstein, Löwenstein, Germany. <sup>8</sup>Department of Internal Medicine, Justus-Liebig-University Giessen, Universities of Giessen and Marburg Lung Center (UGMLC), Giessen, Germany. <sup>9</sup>German Center of Lung Research (DZL), Germany. <sup>10</sup>Department of Rheumatology, University Hospital, Zurich, Switzerland. <sup>11</sup>Universitätsklinikum Bonn, Medizinische Klinik und Poliklinik II, Innere Medizin – Kardiologie/Pneumologie, Bonn, Germany. <sup>12</sup>Universitätsklinikum Carl Gustav Carus der Technischen Universität Dresden, Medizinische Klinik und Poliklinik I, Dresden, Germany. <sup>13</sup>Klinik für Innere Medizin V, Pneumologie, Universitätsklinikum des Saarlandes, Homburg, Germany. <sup>14</sup>Department of Internal Medicine, Respiratory Medicine and Ventilatory Support, Medical Mission Hospital, Central Clinic Würzburg, Würzburg, Germany. <sup>15</sup>Department of Respiratory Medicine, Eppendorf University Hospital, Hamburg, Germany. <sup>16</sup>Department of Respiratory Medicine and Infectious Diseases, Hannover Medical School, Hannover, Germany.

Corresponding author: Marius M. Hoeper ([hoeper.marius@mh-hannover.de](mailto:hoeper.marius@mh-hannover.de))



Shareable abstract (@ERSpublications)

**In patients with pulmonary hypertension, the mortality rate associated with COVID-19 has declined sharply with the emergence of the Omicron variants** <https://bit.ly/42OMsfj>

**Cite this article as:** Schmidt K-H, Milger K, Pausch C, *et al.* Trends in COVID-19-associated mortality in patients with pulmonary hypertension: a COMPERA analysis. *Eur Respir J* 2023; 61: 2202440 [DOI: 10.1183/13993003.02440-2022].

This single-page version can be shared freely online.

Copyright ©The authors 2023.

This version is distributed under the terms of the Creative Commons Attribution Non-Commercial Licence 4.0. For commercial reproduction rights and permissions contact [permissions@ersnet.org](mailto:permissions@ersnet.org)

Received: 20 Dec 2022  
Accepted: 26 March 2023

*To the Editor:*

Patients with pulmonary hypertension (PH) have been among those affected heavily by the coronavirus disease 2019 (COVID-19) pandemic caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). Early case series reported case fatality rates ranging from 19–45% in small series of 11–70 patients with PH who contracted COVID-19 [1–4]. A prospective series of 211 French patients with various forms of PH, who developed COVID-19 between February 2020 and April 2021, found an overall case fatality rate of 24.6% [5].

